Literature DB >> 29986994

Prostate-Specific Antigen Testing Initiation and Shared Decision-Making: Findings from the 2000 and 2015 National Health Interview Surveys.

Jun Li1, Helen Ding2, Thomas B Richards2, Iman Martin2, Sarah Kobrin2, Pamela M Marcus2.   

Abstract

PURPOSES: Despite recommendations against prostate cancer screening with prostate-specific antigen (PSA) tests, about one-fourth of men age ≥40 years received PSA tests in 2015. This study aimed to answer 3 questions for men who had a PSA test in the past year: (1) What percentage of these men received the test first suggested by physicians? (2) What factors were associated with physician-initiated PSA testing (PIPT) versus patient/someone else-initiated testing? (3) What percentage of patients ever had shared decision-making when tests were initiated by physicians?
METHODS: We analyzed the 2000 and 2015 National Health Interview Survey data. We calculated age-standardized prevalence of PIPT for both years. For 2015, we used logistic regression to calculate adjusted prevalence ratios for PIPT. We also calculated the prevalence of ever discussing both advantages and disadvantages.
RESULTS: The age-standardized prevalence of PIPT was significantly higher in 2015 (84.9%) than in 2000 (72.3%). In 2015, nearly 90% of PSA screenings for men aged ≥70 years were suggested by physicians. PIPT was positively associated with 2 or more comorbid conditions and number of patient visits to the doctor. Less than one-third of men reported they had ever participated in a discussion of advantages and disadvantages of PSA testing.
CONCLUSIONS: The majority of men who had PSA testing in the past year reported that their physicians were the first to suggest testing, including men aged ≥70 years. Our study also points to the challenges and needs in conducting shared decision-making before PSA testing in clinical practice. © Copyright 2018 by the American Board of Family Medicine.

Entities:  

Keywords:  Decision Making; Early Detection of Cancer; Logistic Regression; Prevalence; Prostate Cancer; Prostate-Specific Antigen

Mesh:

Substances:

Year:  2018        PMID: 29986994      PMCID: PMC6069516          DOI: 10.3122/jabfm.2018.04.170448

Source DB:  PubMed          Journal:  J Am Board Fam Med        ISSN: 1557-2625            Impact factor:   2.657


  5 in total

1.  The US Preventive Services Task Force 2017 Draft Recommendation Statement on Screening for Prostate Cancer: An Invitation to Review and Comment.

Authors:  Kirsten Bibbins-Domingo; David C Grossman; Susan J Curry
Journal:  JAMA       Date:  2017-05-16       Impact factor: 56.272

2.  National evidence on the use of shared decision making in prostate-specific antigen screening.

Authors:  Paul K J Han; Sarah Kobrin; Nancy Breen; Djenaba A Joseph; Jun Li; Dominick L Frosch; Carrie N Klabunde
Journal:  Ann Fam Med       Date:  2013 Jul-Aug       Impact factor: 5.166

3.  Shared decision making in prostate-specific antigen testing with men older than 70 years.

Authors:  Jun Li; Zahava Berkowitz; Thomas B Richards; Lisa C Richardson
Journal:  J Am Board Fam Med       Date:  2013 Jul-Aug       Impact factor: 2.657

4.  To screen or not to screen, when clinical guidelines disagree: primary care physicians' use of the PSA test.

Authors:  Crystale Purvis Cooper; Tracie L Merritt; Louie E Ross; Lisa V John; Cynthia M Jorgensen
Journal:  Prev Med       Date:  2004-02       Impact factor: 4.018

5.  Patterns of Prostate-Specific Antigen Test Use in the U.S., 2005-2015.

Authors:  Zahava Berkowitz; Jun Li; Thomas B Richards; Pamela M Marcus
Journal:  Am J Prev Med       Date:  2017-10-16       Impact factor: 5.043

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.